Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cabaletta Bio, Inc.

NASDAQ: CABA · Life Sciences · 4 alerts · CIK 1759138

Share price
$1.11Close, Nov 16
Market cap
$239M
Shares outstanding
215.72MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cabaletta Bio, Inc. filings on SEC EDGAR ↗

6:05 AM ET 8-K
Clinical Trial Data

Cabaletta Bio Clinical Trial Data

Cabaletta Bio presented Phase 1/2 clinical data for rese-cel (CABA-201) at the ACR Convergence 2026 meeting, demonstrating durable, immunomodulator-free responses across multiple autoimmune diseases. Key results showed 100% of dermatomyositis patients maintained moderate-to-major improvement scores through one year and 100% of biopsied lupus nephritis patients achieved DORIS remission. The company plans to report topline registrational data in H2 2027 and submit a Biologics License Application in Q1 2028.

“In three different autoimmune diseases where patients are at risk of severe disability, end-organ damage, and increased risk of death despite current therapies, a single weight-based dose of rese-cel delivered immunomodulator-free clinical improvements that were durable through at least one year with a favorable benefit-risk profile.”

David J. Chang, M.D., Chief Medical Officer of Cabaletta

“We believe these emerging data reinforce the potential of rese-cel to deliver an immune reset that leads to durable efficacy with a favorable benefit-risk profile for autoimmune disease patients.”

David J. Chang, M.D., Chief Medical Officer of Cabaletta
7:35 AM ET 10-Q
Financial Results

Cabaletta Bio Q3 2026 Results: Net Loss of $53.1M, Loss Widens

Cabaletta Bio is a late-stage clinical biotechnology company focused on autoimmune diseases, specifically advancing its Phase 1/2 RESET clinical trials for rese-cel. As of October 30, 2026, the company reported 215,720,392 shares of common stock outstanding and continues to incur significant losses to fund its R&D and manufacturing partnerships with Lonza and Cellares.

Key figure
Net loss $53.1M
7:31 AM ET 8-K
Financial Results

Cabaletta Bio Financial Results

Cabaletta Bio reported third quarter 2026 financial results, highlighting a cash position of $299.4 million which extends its operational runway into Q1 2028. The company announced plans for a BLA submission for rese-cel in myositis in Q1 2028 and initiated a second registrational study in systemic sclerosis. Management noted a recent increase in enrollment activity following a slower period in Q3 2026.

Term
Q3 2026

“We are encouraged by the favorable benefit-risk profile observed with rese-cel to date as we made deliberate choices, including construct design, standard and well-characterized manufacturing, and weight-based dosing, from the outset of its development to prioritize patient safety.”

Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta

“We are now seeing increased enrollment and screening activity, with multiple patients enrolled in the past few weeks in the registrational adult myositis study, after a slower period in 3Q26 that we believe was influenced by patient and physician caution following recently reported safety events from others in the field.”

Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta
8:01 AM ET 8-K
Capital Raise

Cabaletta Bio Capital Raise of $128M

Cabaletta Bio announced the completion of warrant exercises from its June 2025 public offering, resulting in total aggregate gross proceeds of approximately $128.2 million. The warrants, which had an exercise price of $2.50 per share, expired on September 12, 2026, with the vast majority of exercises occurring between July 1, 2026, and the expiration date.

Value
$128M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.